Abstract 1177P
Background
Sonidegib is a Hedgehog pathway inhibitor approved for the treatment of locally advanced basal cell carcinoma (laBCC) in the US, EU, Switzerland, and Australia, and metastatic BCC (mBCC) in Switzerland and Australia not amenable to curative surgery or radiotherapy. This analysis compared tumour burden reduction using photography or magnetic resonance imaging (MRI) in patients with laBCC that had a time to first tumour response (TFTR) within 6 months of starting treatment.
Methods
The double-blind, multicentre, phase II BOLT study assessed the efficacy and safety of sonidegib 200 mg with laBCC. Tumour burden reduction was assessed using both colour photography and MRI by central review. Tumour response was defined as a >10 mm unidimensional decrease in tumour size. Safety assessments included adverse event (AE) monitoring.
Results
Overall, among 66 patients with laBCC receiving sonidegib 200 mg, TFTR <3 months was achieved by 31 patients per photography and 11 patients per MRI assessment; TFTR from 3 to <6 months was achieved by 8 patients per photography and 12 per MRI. For patients with a TFTR of <3 months, the median (minimum, maximum) percent change from baseline in tumour size was −18.5 (−100.0, 35.9) vs −23.8 (−100.0, −11.9) at 9 weeks, −33.4 (−100.0, 38.5) vs −54.0 (−100.0, −27.1) at 25 weeks, −30.7 (−100.0, 12.0) vs −82.1 (−100.0, −52.9) at 41 weeks, and −29.0 (−100.0, 57.8) vs −82.1 (−100.0, −58.8) at 61 weeks per photography vs MRI, respectively. For patients with a TFTR from 3 to <6 months, the median (minimum, maximum) percent change from baseline in tumour size was not available at 9 weeks, −16.0 (−100.0, 18.1) vs −37.0 (−77.3, −12.5) at 25 weeks, −32.9 (−54.7, 22.3) vs −79.2 (−100.0, −41.5) at 41 weeks, and −35.1 (−46.8, −23.4) vs −77.3 (−100.0, −31.6) at 61 weeks per photography vs MRI, respectively. Sonidegib was well tolerated, and most AEs were Grade 1/2 in severity.
Conclusions
In patients with a TFTR within 6 months of starting treatment with sonidegib, an overall greater reduction in tumour size was reported per MRI assessment vs photography, with photography underestimating the extent of tumour response.
Clinical trial identification
NCT01327053.
Editorial acknowledgement
Writing and editorial support were provided by Duncan McCloskey, PhD, of AlphaBioCom, a Red Nucleus company, and funded by Sun Pharma.
Legal entity responsible for the study
Sun Pharma.
Funding
Sun Pharma.
Disclosure
R. Gutzmer: Non-Financial Interests, Personal, Speaker, Consultant, Advisor: Almirall, Amgen, Bristol Myers Squibb, Immunocore, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi Genzyme, Sun Pharmaceutical Industries, Inc., 4SC, Bayer; Non-Financial Interests, Personal, Research Funding: Amgen, Johnson & Johnson, Merck Serono, Novartis; Financial Interests, Advisory Board: Sun Pharmaceutical Industries, Inc. F. Kiecker: Financial Interests, Personal, Research Grant: Amgen, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sanofi. C. Loquai: Non-Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Roche, Novartis, Merck Sharp & Dohme. R. Dummer: Non-Financial Interests, Personal, Advisory Board: Amgen, Bristol Myers Squibb, CatalYm, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sanofi, Second Genome, Sun Pharmaceutical Industries, Inc., Takeda. A. Hauschild: Non-Financial Interests, Personal, Speaker, Consultant, Advisor: Roche, Novartis, Amgen, Celgene, GSK, MedImmune, MelaSciences, Merck Serono, OncoSec, Eisai; Non-Financial Interests, Personal, Research Funding: Roche, Novartis, Amgen, Celgene, GSK, MedImmune, MelaSciences, Merck Serono, OncoSec, Eisai. N. Squittieri, R. Arntz, S. Martelli, J. Dierlamm: Financial Interests, Personal, Full or part-time Employment: Sun Pharmaceutical Industries Inc. C. Robert: Non-Financial Interests, Personal, Speaker, Consultant, Advisor: Amgen, Array BioPharma, Bristol Myers Squibb, Merck, Merck Serono, Novartis, Pierre Fabre, Roche.
Resources from the same session
1100P - Open-label non-randomized phase IB study to characterize the safety, tolerability and recommended dose of tinostamustin in combination with nivolumab in patients with advanced melanoma (ENIGMA)
Presenter: Markus Joerger
Session: Poster session 13
1101P - The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma
Presenter: Jordi Rodon
Session: Poster session 13
1102P - Evaluation of surrogate endpoints for overall survival within the RELATIVITY-047 trial
Presenter: Peter Mohr
Session: Poster session 13
1103P - Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year subgroup analyses from RELATIVITY-047
Presenter: Georgina Long
Session: Poster session 13
1104P - Efficacy of immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD1 treatment: A EUMelareg real-world evidence study
Presenter: Michael Weichenthal
Session: Poster session 13
1105P - First-line nivolumab plus ipilimumab in advanced melanoma patients previously treated with adjuvant systemic therapy
Presenter: Katarzyna Kozak
Session: Poster session 13
1106P - Anti-PD-1 (PD1) monotherapy or in combination with anti-CTLA-4 for metastatic melanoma (MM) patients (pts) with liver metastases (mets)
Presenter: Ines Pires da Silva
Session: Poster session 13
1107P - BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma
Presenter: Alexander Shoushtari
Session: Poster session 13
1108P - Outcomes of patients with unresectable or metastatic melanoma after cessation of immunotherapy following complete response or toxicities
Presenter: Nur Sakinah Zulkifli
Session: Poster session 13